Alnylam Pharmaceuticals (ALNY) Total Current Liabilities (2009 - 2026)

Alnylam Pharmaceuticals has reported Total Current Liabilities for 18 years, with the latest figure at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 25.46% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 25.46% YoY), and the FY2025 full-year result was $1.5 billion, up 23.61% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $1.3 billion, down from $1.5 billion in the prior quarter.
• The five-year high for Total Current Liabilities was $1.6 billion in Q3 2025, with the low at $606.0 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $1.0 billion across 5 years, with a median of $967.8 million in 2023.
• Annual changes were most pronounced in 2022 — Total Current Liabilities climbed 10.38% — and 2024, when it surged 39.85%.
• Alnylam Pharmaceuticals' Total Current Liabilities stood at $767.9 million in 2022, then increased by 26.03% to $967.8 million in 2023, then rose by 22.58% to $1.2 billion in 2024, then increased by 23.61% to $1.5 billion in 2025, then decreased by 7.97% to $1.3 billion in 2026.
• The last three Total Current Liabilities figures came in at $1.3 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.6 billion (Q3 2025), per Business Quant data.